Stereotactic Radiotherapy in Tumor Ablation (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 63
Special Issue Editors
Interests: stereotactic body radiotherapy; re-irradiation; lattice radiotherapy; thoracic radiotherapy
Special Issues, Collections and Topics in MDPI journals
Interests: head and neck radiotherapy; flash radiotherapy; stereotactic body radiotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We would like to cordially invite you to contribute to the collection of articles related to "Stereotactic Radiotherapy in Tumor Ablation".
In the last decade, we have seen a growing interest in oncology for stereotactic body radiotherapy (SBRT), which appears as a highly effective, non-invasive, and safe tumor ablative treatment.
SBRT is building on major improvements in delivery achieved by intensity-modulated and image-guided radiotherapy, which now permit safe ablative doses of radiation to be delivered. SBRT is increasingly being used to treat a variety of cancers, including primary tumors as well as metastases in a wide range of locations (brain, bone, lung, prostate, liver, etc.).
Accumulated clinical evidence is growing over time, with efficacy and safety having being demonstrated in randomized clinical trials.
This collection of articles aims to provide a comprehensive and broad overview of the use of SBRT in the central nervous system, head and neck, thorax, abdomen, and pelvis, as well as its use in re-irradiation or metastatic and oligometastatic settings. Discussions on the technical evolutions, biological background, new developments, and potential limitations are encouraged. The remarkable complementarity of SBRT with systemic treatments is also important to emphasize.
Our goal is to create a reliable and updated source of information for all physicians and oncologists and improve cancer care through the use of this cutting-edge technology.
We look forward to receiving your contributions to this Special Issue of the journal Cancers.
Dr. Rémy Kinj
Prof. Dr. Jean Bourhis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SBRT
- stereotactic body radiotherapy
- SABR
- stereotactic ablative radiotherapy
- re-irradiation
- oligometastasis
- local therapy
